UK markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8900-0.0100 (-0.53%)
At close: 04:00PM EDT
1.9000 +0.01 (+0.53%)
After hours: 06:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9000
Open1.8400
Bid1.8500 x 800
Ask1.8900 x 1800
Day's range1.8400 - 1.9200
52-week range1.0800 - 3.5800
Volume300,331
Avg. volume487,635
Market cap158.191M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-0.6380
Earnings date17 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.50
  • Zacks

    ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

    ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

  • Globe Newswire

    ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

    -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well as development, commercial, and sales-based milestone payments- -In the United States, the New Drug Application (NDA) for linzagolix is currently under review by the Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) target acti

  • Globe Newswire

    ObsEva Announces Corporate Updates

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc.